No, lifelong Arimidex (anastrozole) is not recommended for males with elevated estrogen
There is no evidence supporting lifelong anastrozole use in men with high estrogen, and the available guidelines explicitly state that aromatase inhibitors should not be used in males outside of specific breast cancer contexts. The evidence provided addresses anastrozole use exclusively in postmenopausal women for breast cancer risk reduction or treatment, not for managing elevated estrogen in otherwise healthy men.
Critical Evidence Gaps
The guideline evidence is entirely focused on postmenopausal women with breast cancer or at high risk for breast cancer. The ASCO guidelines explicitly state that "clinicians should not prescribe anastrozole, exemestane, or raloxifene for breast cancer risk reduction in premenopausal women" 1. While this addresses women specifically, it underscores that aromatase inhibitors are indicated only for specific cancer-related scenarios, not general hormonal management.
The only male-specific guideline addresses male breast cancer patients, where tamoxifen (not anastrozole) is the first-line endocrine therapy 2. Men with hormone receptor-positive breast cancer should receive tamoxifen for 5 years, with consideration of extending to 10 years in high-risk cases. Anastrozole plus a GnRH agonist/antagonist is reserved only for men with contraindications to tamoxifen.
Research Evidence in Men Shows Short-Term Use Only
The research studies examining anastrozole in men demonstrate:
- Short-term studies only: Studies evaluated 10-12 weeks of treatment 3, 4, 5, not lifelong therapy
- Modest estradiol reduction: Estradiol decreased approximately 48-50% but remained within normal male ranges 4, 5
- No demonstrated clinical benefits: No improvements in quality of life, sexual function, or body composition were observed 4
- Bone safety concerns: While 12-week studies showed no adverse bone effects 3, longer-term data in women demonstrate increased fracture risk and bone loss 1, 6
One study of men on testosterone therapy with elevated estradiol showed that anastrozole 0.5 mg three times weekly effectively reduced estradiol levels from median 65 pg/mL to 22 pg/mL 7. However, this was used as adjunctive therapy to manage a side effect of testosterone replacement, not as standalone lifelong treatment.
Significant Safety Concerns for Long-Term Use
The FDA label and guidelines for women reveal substantial risks with prolonged aromatase inhibitor use 8:
- Bone loss and fractures: Increased fracture risk (NNH = 72) and accelerated bone mineral density loss 6
- Cardiovascular events: Increased odds of cardiovascular events (OR 1.18, NNH = 122) 6
- Musculoskeletal toxicity: Joint stiffness, arthralgias, myalgia in 53-69% of patients 1, 6
- Other adverse effects: Hypertension, dry eyes, vaginal dryness (in women), and increased treatment discontinuation 1
Appropriate Clinical Approach
If a man has elevated estrogen, the focus should be on identifying and treating the underlying cause rather than chronic estrogen suppression:
- Evaluate for pathologic causes: Testicular tumors, liver disease, obesity, medications, exogenous estrogen exposure
- If on testosterone therapy: Consider dose adjustment, formulation change, or short-term anastrozole (0.5 mg 3x/week) only if estradiol >60 pg/mL or >40 pg/mL with symptoms 7
- Monitor bone health: If any aromatase inhibitor use is considered, baseline and serial bone density monitoring is mandatory 1
- Time-limited therapy: Even in the testosterone therapy context, anastrozole should be used intermittently to manage symptoms, not indefinitely 7, 9
The recommended duration in all evidence-based contexts is 5 years maximum 1, and this applies only to postmenopausal women with breast cancer indications. There is no evidence supporting lifelong use in any population, and certainly not in men with isolated elevated estrogen levels.